Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors
Status:
Active, not recruiting
Trial end date:
2023-12-11
Target enrollment:
Participant gender:
Summary
Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate
may fight breast cancer by blocking the use of estrogen by the tumor cells
This phase IIb trial studies how well low-dose tamoxifen citrate works in reducing breast
cancer risk in radiation-induced cancer survivors.
Phase:
Phase 2
Details
Lead Sponsor:
University of Alabama at Birmingham
Collaborators:
City of Hope National Medical Center Dana-Farber Cancer Institute M.D. Anderson Cancer Center Mayo Clinic National Cancer Institute (NCI) St. Jude Children's Research Hospital University Health Network, Toronto University of Chicago University of Colorado, Denver University of Michigan University of Minnesota University of Minnesota - Clinical and Translational Science Institute University of Washington Wake Forest University Wake Forest University Health Sciences need to be deleted